Market Place
Sourcing Support
Neuraxpharm Reports Sustained Growth & International Expansion
14 Nov 2024 //
PR NEWSWIRE
Neuraxpharm expands operations into the Middle East
01 Oct 2024 //
PR NEWSWIRE
Neuraxpharm to Utilize Veeva Quality Applications
25 Jul 2024 //
CONTRACT PHARMA
Neuraxpharm agrees on divestment of inhalation API specialist Inke to Keensight
12 Jun 2024 //
PRESS RELEASE
Neuraxpharm`s Briumvi (ublituximab) Receives Approval in Europe
19 Feb 2024 //
EMA
EC revokes all centrally granted generic marketing permissions for DMF
20 Dec 2023 //
PR NEWSWIRE
TG Therapeutics and Neuraxpharm Announce Agreement for BRIUMVI
01 Aug 2023 //
GLOBENEWSWIRE
Neuraxpharm expands outside Europe into Brazil and Mexico
11 Jul 2023 //
PR NEWSWIRE
Neuraxpharm announces closing of acquisition of established products from Sanofi
01 Feb 2023 //
PR NEWSWIRE
Neuraxpharm completes its presence in Benelux by opening an affiliate
24 Jan 2023 //
PR NEWSWIRE
Neuraxpharm expands into the Netherlands
07 Dec 2022 //
PRNEWSWIRE
Minoryx and Neuraxpharm team to provide new therapy for rare CNS disorders
10 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Neuraxpharm partners with mjn-neuro on epilepsy wearable
26 Oct 2022 //
PHARMAPHORUM
Neuraxpharm steps into the Digital Health market with a wearable device
25 Oct 2022 //
PRNEWSWIRE
Neuraxpharm launches European campaign to increase awareness of medical cannabis
19 Oct 2022 //
PR NEWSWIRE
Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe
06 Oct 2022 //
PRNEWSWIRE
Sanofi is offloading 17 meds from its pain and CNS rosters
13 Jul 2022 //
FIERCEPHARMA
Neuraxpharm to increase branded business through upcoming acquisition from Sanofi
12 Jul 2022 //
PR NEWSWIRE
Neuraxpharm Generic Dimethyl fumarate Receives Approval in Europe
13 Jun 2022 //
EMA
Neuraxpharm appoints Alfredo Barón as Country Manager for Spain
01 Jun 2022 //
PRNEWSWIRE
Inke to triple capacity for inhalation API manufacturing
20 Apr 2022 //
PRESS RELEASE
Neuraxpharm appoints Monica Torrecilla as Country Manager for Portugal
22 Mar 2022 //
PRNEWSWIRE
Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland
14 Mar 2022 //
PRNEWSWIRE
Neuraxpharm expands in Southeast Europe
08 Mar 2022 //
PHARMAFILE
Neuraxpharm expands its business in Southeast Europe
08 Mar 2022 //
PRNEWSWIRE
Panaxia & Neuraxpharm: First export of medical cannabis sublingual tab to France
24 Jan 2022 //
PR NEWSWIRE
Panaxia and Neuraxpharm Expands Strategic Collaboration to Poland
19 Aug 2021 //
PRNEWSWIRE
Panaxia and Neuraxpharm will be first to launch Medical Cannabis Extracts
21 Jun 2021 //
PRNEWSWIRE
Neuraxpharm appoints commercial expert Dr. Maximilian von Wülfing COF
01 Jun 2021 //
PRNEWSWIRE
Neuraxpharm selected for prestigious pilot program to supply medical in France
28 Jan 2021 //
PRNEWSWIRE
Neuraxpharm launches first product in Japan
12 Jan 2021 //
PRNEWSWIRE
Neuraxpharm launches first product in Japan
11 Jan 2021 //
PRNEWSWIRE
Neuraxpharm establishes operations in the Republic of Ireland the acquisition
14 Dec 2020 //
PRNEWSWIRE
Neuraxpharm acquires Medinutrix; establishes operations in Republic of Ireland
14 Dec 2020 //
PHARMABIZ
Tris & Neuraxpharm Group Announce Partnership to Tris` Quillivant XR
08 Dec 2020 //
PRNEWSWIRE
Panaxia and Neuraxpharm Expand Strategic Collaboration to France
23 Nov 2020 //
PRNEWSWIRE
Permira funds to acquire leading European CNS specialty pharmaceutical company Neuraxpharm
22 Sep 2020 //
PRESS RELEASE
Neuraxpharm acquires market-leading value-added product for emergency
14 Sep 2020 //
PRNEWSWIRE
Neuraxpharm acquires market-leading value-added product for emergency treatment of epileptic children
14 Sep 2020 //
PRNEWSWIRE
Apax mulls sale of Neuraxpharm to lock in pharma sector premium: sources
09 Jul 2020 //
REUTERS
Almirall Divests Ansiolin To Neuraxpharm In Italy
26 Jun 2020 //
REUTERS
Blazing the Trail to EU Exports: Panaxia Israel Announces- EU-GMP Certification
11 Jun 2020 //
PR NEWSWIRE
Neuraxpharm Enters the Medical Cannabis Market as the First-ever European Pharma
01 Apr 2020 //
PR NEWSWIRE
Neuraxpharm launches first products in UK
30 Mar 2020 //
PHARMATIMES
Neuraxpharm Unveils their First ever Products in UK
25 Mar 2020 //
BIOPHARMAPRESS
Neuraxpharm to launch its first probiotic product in Europe
24 Mar 2020 //
PHARMACEUTICAL
Neuraxpharm turning heads with growth in European CNS market
24 Mar 2020 //
THEPHARMALETTER
German Neuraxpharm reinforces presence in Poland
28 Feb 2020 //
BBJ
Neuraxpharm Buys Glenmark’s Polish CNS Assets
25 Feb 2020 //
PHARMAINTELLIGENCE
Neuraxpharm Reinforces Presence In Poland With The Acquisition Of Glenmark’S Cns Product Portfolio
25 Feb 2020 //
PRESS RELEASE
Neuraxpharm Acquires Farmax Expands In Eastern Europe
01 Feb 2020 //
INDUATRY
Neuraxpharm Underlines OTC Ambitions With Easypharm Acquisition
24 Jan 2020 //
PHARMAINTELLIGENCE
European CNS Specialist Neuraxpharm Strengthens Expansion into Austrian Market
23 Jan 2020 //
PR NEWSWIRE
Divisive `dividend recap` deals return in red hot debt market
22 Jan 2020 //
REUTERS
European CNS Specialist Neuraxpharm Expands Southern European Presence
29 Nov 2019 //
PR NEWSWIRE
Neuraxpharm Expands Southern European Presence With Expansion Into Portugal
28 Nov 2019 //
PRESS RELEASE
Neuraxpharm Buys Into Cannabidiol Business
29 Oct 2019 //
PHARMAINTELLIGENCE
BRIEF—Neuraxpharm buys cannabidiol company
29 Oct 2019 //
THEPHARMALETTER
European CNS Specialist Neuraxpharm Enters Booming CBD Market
29 Oct 2019 //
PR NEWSWIRE
European CNS Specialist Neuraxpharm Enters Booming CBD Market
28 Oct 2019 //
PRNEWSWIRE
